Product Overview

Vildagliptin Sustained Release 100 Mg (Generic) is a prescription oral medication indicated for the management of Type 2 diabetes mellitus. Manufactured by Cipla Limited, this formulation belongs to the class of dipeptidyl peptidase‑4 (DPP‑4) inhibitors and is designed to provide prolonged glucose‑lowering activity through a sustained‑release mechanism. The product is supplied in packs containing 15 tablets per strip, with available pack sizes of 60, 120, and 240 tablets, offering flexibility for long‑term therapy.

What is Vildagliptin Sustained Release 100 Mg (Generic)?

Vildagliptin is a synthetic small‑molecule drug that selectively inhibits the enzyme DPP‑4, which plays a key role in regulating incretin hormones such as glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By blocking DPP‑4, vildagliptin enhances the incretin effect, leading to increased insulin secretion, decreased glucagon release, and reduced hepatic glucose production. The sustained‑release technology ensures a gradual release of the active ingredient over 24 hours, allowing once‑daily dosing and improved pharmacokinetic consistency.

Uses and Benefits

This medication is primarily used as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes who have not achieved target glucose levels with metformin or other oral agents. Clinical studies have demonstrated that vildagliptin provides modest but clinically meaningful reductions in HbA1c, fasting plasma glucose, and post‑prandial glucose excursions, with a low risk of hypoglycemia when used alone or in combination with metformin. Additional benefits include weight neutrality and a favorable safety profile compared with some sulfonylureas.

Patients often appreciate the convenience of a once‑daily tablet and the absence of frequent dosage adjustments. Moreover, the sustained‑release formulation may improve adherence, a critical factor in chronic disease management.

How It Works

The pharmacodynamics of vildagliptin involve inhibition of the DPP‑4 enzyme, which normally degrades incretin hormones. By preserving these hormones, vildagliptin enhances glucose‑dependent insulin release while suppressing glucagon secretion, resulting in a balanced effect on blood glucose levels without causing excessive drops. The sustained‑release matrix delays absorption, leading to a slower peak concentration (Cmax) and a more stable plasma concentration over the dosing interval, which translates into consistent therapeutic effect throughout the day.

Dosage Guidelines

The recommended adult dosage is one 100 mg tablet taken orally once daily, with or without food, as prescribed by a healthcare professional. Dosage adjustments are not routinely required in patients with mild to moderate hepatic impairment, but severe hepatic dysfunction may necessitate a reduced dose. In patients with renal impairment, dose modification is generally not needed unless creatinine clearance falls below 30 mL/min, in which case caution is advised. It is essential to follow the prescribing physician’s instructions and to undergo regular laboratory monitoring of renal function and glycemic control.

Side Effects

Like all medications, vildagliptin may cause adverse effects. The most commonly reported side effects include nasopharyngitis, urinary tract infections, and headache, which are usually mild and self‑limiting. Less frequent but clinically important adverse events can involve pancreatitis, severe joint pain, and hypersensitivity reactions such as rash or angio‑edema. Patients should discontinue the medication and seek medical attention if they experience persistent abdominal pain, severe joint swelling, or signs of an allergic reaction.

Warnings and Precautions

Healthcare providers should evaluate patients for a history of pancreatitis, severe renal impairment, or known hypersensitivity to vildagliptin before initiating therapy. Caution is advised in patients with type 1 diabetes, diabetic ketoacidosis, or a history of allergic reactions to similar DPP‑4 inhibitors. Concomitant use with strong CYP3A4 inducers or inhibitors may alter drug levels; therefore, a review of current medications is recommended. Pregnant and lactating women should only use this medication if the potential benefit justifies the potential risk, and they must consult their physician.

Frequently Asked Questions

Q: Can vildagliptin be used together with insulin?

A: Yes, vildagliptin can be added to insulin therapy, but dosage adjustments of insulin may be necessary to avoid hypoglycemia. Close glucose monitoring is recommended.

Q: How long does it take to see a reduction in HbA1c?

A: Clinical trials have shown modest HbA1c reductions after 12‑24 weeks of consistent use, though individual response may vary.

Q: Is the medication safe for elderly patients?

A: Elderly patients can use vildagliptin, but clinicians should assess renal function and comorbidities, as older adults may have reduced kidney clearance.

Q: Does the drug cause weight gain?

A: Vildagliptin is generally weight‑neutral; it does not typically lead to significant weight gain or loss.

Q: Where can I find more detailed prescribing information?

A: The full prescribing information is available on the FDA label page and can be accessed through the Drugs.com database for patient‑friendly summaries.

For additional scientific background, refer to resources such as the National Institutes of Health (NIH) diabetes fact sheet (niddk.nih.gov/health-information/diabetes) and the FDA’s drug label database (fda.gov/drugs/drug-approvals-and-databases/drug-label-information).

Related Products

• Misoprost 600 mcg (Misoprostol)
• Misoprost (Misoprostol)
• Misoprost 200 mcg (Misoprostol)
• Misoprostol 600 mcg (Generic)
• Misoprostol 200 mcg (Generic)
• Pantosec D SR (Pantoprazole/Domperidone)
• Pantosec D 50 Mg (Pantoprazole/Domperidone)
• Rabicip 10 mg (Rabeprazole)
• Rabicip (Rabeprazole)
• Pantosec 40 mg (Pantoprazole)
• Rabicip 20 mg (Rabeprazole)
• Rabeprazole 20 mg (Generic)